National Survey on Gastroesophageal Reflux Disease (GERD) Patients - Full Text View

National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

This study has been completed.

First Received on June 10, 2008. Last Updated on August 4, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00695838

Purpose

The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .

Condition
GERD

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice

Resource links provided by NLM:

MedlinePlus related topics: GERD

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Secondary Outcome Measures:

Groups/Cohorts
1

Eligibility

Study Population

First three consecutive patients with GERD symptoms seen by GP

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695838

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Alain Castaigne, Medical Director

AstraZeneca

More Information

No publications provided

Responsible Party:	Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00695838 History of Changes
Other Study ID Numbers:	NIS-GFR-DUM-2007/3
Study First Received:	June 10, 2008
Last Updated:	August 4, 2009
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

GERD symptoms- Waist circumference
Patients with symptomatic GERD

Additional relevant MeSH terms:

Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders

Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on February 09, 2012